All posts by imreal

NeuroFlow Expands Clinical Referral Network, Partnering with Specialty Providers


NeuroFlow, the market leader in behavioral healthcare technology infrastructure, has added three new partners to its Clinical Referral Network in order to help more individuals get access to behavioral health. Joining the referral network will be:


  • Bicycle Health (Boston, MA) – The leading telehealth provider of integrated medical and behavioral health care for opioid use disorder (OUD) in the United States offers confidential physician visits, lab testing, individual and group therapy, and prescriptions for Suboxone™.
  • Brave Health (Miami, FL) – A virtual mental health provider dedicated to helping people thrive by engaging them in high-quality, affordable, and easily accessible mental health care, including individual therapy, medication management, and specialized therapy groups.
  • Monument (New York City, NY) – Monument is a digital health platform for anyone looking to change their relationship with alcohol. Monument connects members to virtual evidence-based care including behavioral therapy, medication-assisted treatment, and peer support.

Launched in August 2022, the initial cohort of partners included AbleTo, Array Behavioral Care, Brightside Health, LifeStance Health, and Marvin, each with a distinct purview into – and solution to address – the national mental health crisis, which affects nearly 50 million Americans.

This new round of partners significantly builds upon the coverage area of the initial group of companies, with a heightened focus on substance use and Medicaid members. Substance use costs inpatient and emergency services departments a disproportionate amount over time, totaling approximately $13 billion per year. Additionally, many outpatient providers of mental health care do not cover Medicaid patients and it is critical to support the needs of this growing population.

“Technology companies have the means and a mandate to help reach more people who are disconnected from the healthcare system and struggle to find the care they need for their own mental health, or the health of a loved one,” said Parker Reynolds, Head of Strategic Partnerships at NeuroFlow. “With this expanded roster of partners, we have significantly improved our ability to refer and support individuals on Medicaid as well as those with substance use disorders.”

Individuals seeking mental health treatment often have a wide range of clinical needs, some more urgent than others. By continuing to expand and cover a diversity of behavioral health need areas, the Clinical Referral Network can help to ensure that the right care is available to individuals at the time that they need it. NeuroFlow will continue to identify additional opportunities within their partner network moving forward. If you are a clinical service provider interested in joining the network, visit the partners webpage or reach out to parker@neuroflow.com.

About NeuroFlow

NeuroFlow provides the technology infrastructure that leading healthcare organizations need to deliver effective and scalable integrated programs that improve access to behavioral healthcare and lower costs. Powered by proof and clinical expertise, NeuroFlow’s next generation software enables programs to bridge the gap between physical and mental health with proven solutions for psychiatric collaborative care, suicide prevention, and more. To learn more, visit http://www.neuroflow.com

Share article on social media or email:

“Evolve School of Learning” Using Creative Fund Raising Efforts


All inclusive school opening in August 2023

Evolve School of Learning Filling a Need in Tampa Bay

“We are challenging ourselves to create a school community: one that embraces each individual, respects and builds on each person’s abilities, supports them in the classroom and the community, and is still a part of their lives as they transition into adulthood.”

Evolve School of Learning’s founders are April Hurley and Lindsey Meyer. Meyer and Hurley also co-founded “Bridging The Gap Therapy Solutions” (BTG), a clinic that serves the needs of individuals with various disabilities, challenging behaviors, and emotional disorders. “Bridging the Gap aims to transition kids into schools that support children and young adults at their level, said Hurley.

“It was evident from the onset there was a shortage of these private schools in the Tampa Bay Area. We could not ignore so many of our families who have come to us with their stories of disappointment, abandonment, and rejection from public and private schools alike,” added Meyer. “We are challenging ourselves to create a school community that embraces each individual, respects and builds on each person’s abilities, supports them in the classroom and the community, and is still a part of their lives as they transition into adulthood.” The School will open in August 2023.

Parents and therapists created Evolve Foundation Corp. to support the mission and build Evolve School of Learning. Michelle Crespi, a founding member of Evolve Foundation Corp., realized that Taylor Swift was coming to Tampa Bay during Autism Awareness month. “We have ambitious goals committed to supporting the growth and development of Evolve School of Learning,” said Crespi. Crespi, a speech therapist who has worked alongside BTG for years, had several students draw pictures of Swift with her famed guitar.

Evolve School of Learning will offer students the opportunity to be surrounded by an environment of acceptance and understanding while equipping them with the skills to become strong and empowered individuals as they transition into adulthood and the community. “We will also create tailored learning plans for each student to develop the skills and passions necessary for long-term success,” added Hurley. “Our ultimate goal is to be the catalyst of success for the students we serve by ensuring their social and emotional well-being.”

Evolve Foundation still has a lot to accomplish. They are hiring Florida Certified teachers for the Fall 2023 school year. In addition, they are raising funds to support the School construction, classroom furniture, materials and supplies, and outdoor playground with a safety fence. Those interested in donating can do so by going to evolvefoundationcorp.org/

Share article on social media or email:

New Doctor-Formulated Energy Supplement Electrolyte Boost, Powered by Cognizin®, Boost Without Water Debuts


Electrolyte Boost HYDRATION ELEVATION

Skinz.gg today announced the launch of Electrolyte Boost, a doctor-formulated and water-free electrolyte support product . By eliminating water, the primary delivery mechanism for critical electrolytes, Electrolyte Boost provides a simple, fast, great-tasting way to replace minerals and deliver nutrients to your cells to support overall hydration and activity.

“We are continually looking at how active people’s lives are changing and how to fulfill their need for efficient, yet multi-functional health and performance support,” noted Gary Kleinman, Founder and CEO, Skinz.gg. “Our goal is to provide consumers nationwide with clinically proven health and wellness products that simply and effectively fit into their busy lifestyle.”

Electrolyte Boost is absorbed by the cheek and tongue, entering the bloodstream faster than passing through the stomach and intestines. Each single-serve sachet has 3x the electrolytes of water or sports drinks alone, and 75% more electrolytes than products currently on the market. It also provides vitamins and other essential nutrients, and the 250 mg per serving of Cognizin® Citicoline to boosts brain health, attention, and focus. Electrolyte Boost has zero grams of sugar, making it a low-calorie option for anyone in need of a boost. Electrolyte Boost also extends activity without a bathroom break!

“We are excited to have Cognizin® Citicoline featured as a key ingredient in Skinzz.gg Electrolyte Boost,” says Karen Todd, MBA, RD, Vice President of Global Brand Marketing, Kyowa Hakko USA, Inc. “This innovative formula and unique water-free delivery system supports our goal of advancement and innovation within the brain health arena.”

The revolutionary way that Electrolyte Boost maintains proper electrolyte balance is by reducing the dependency on fluids, which means less urination, thereby maintaining a more extended electrolyte balance in the body. When a person sweats, electrolytes are also excreted from the body. Electrolytes are essential because they are what your cells (especially nerve, heart, and muscle cells) use to maintain electrical communication with cell membranes and carry electrical impulses (nerve impulses, muscle contractions) to other cells. Your kidneys keep the electrolyte concentrations in your blood constant despite changes in your body.

To learn more about Cognizin® Citicoline, please visit: https://cognizin.com

To purchase Skinz.gg’s Electrolyte Boost, please visit: https://electrolyteboost.com

About Cognizin® Citicoline:

Cognizin® Citicoline, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and branded form of Citicoline, a natural substance made endogenously in the body and especially vital to brain health. Citicoline is a potent brain-health nutrient. A proprietary form of citicoline, Cognizin® has been clinically studied to support mental energy, focus, attention, and recall. Cognizin® is manufactured through a fermentation process to yield high quality and high purity. Cognizin® is also highly stable, GRAS, ultra-pure, and allergen-free. For more information on Cognizin®, visit Cognizin.com.

About Kyowa Hakko USA:

Kyowa Hakko USA is the North & South American office of Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing pharmaceuticals, nutraceuticals, and food & beverage products. Kyowa is the maker of branded ingredients, including IMMUSE™ LC-Plasma, Eyemuse™ Lacticaseibacillus paracasei KW3110, Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as L-Alanyl-L-Glutamine. For more information, visit http://www.kyowa-usa.com.

About Skinz.gg:

Skinz.gg is dedicated to “Powering Your Performance” as a global provider of clinically proven health and wellness products. Skinz.gg is on a mission to deliver ease and health to active individuals. The company’s goal is to study and understand how people live their lives and provide supplements to support them in all their activities in the most efficient, simple and satisfying manner.

Media Contacts:

Giselle Chollett

giselle@adinnyc.com

917.386.7116.

Sandra Correa

Impact Partners for Skinz.gg

sandra.correa@impactpartners.llc

917.319.8472

Share article on social media or email:

Biomeme Supports Biosecurity Surveillance Program Launched by Ginkgo Bioworks and the Ukraine Ministry of Health


Our partnership with Concentric by Ginkgo continues to strengthen because of our alignment and focus on Biosecurity. We share in their belief that a “biosecurity in a box” model could be a way to manage biosecurity concerns in crisis zones, hard-to-reach environments, and low-resource areas.

Ginkgo Bioworks and the Public Health Center of the Ukraine Ministry of Health announced the launch of a pilot program for wastewater-based pathogen monitoring, in partnership with Biomeme. The goal of this program is to provide continuous data on infectious pathogens, such as SARS-CoV-2 and influenza, to minimize the impact of infectious diseases on the people of Ukraine. This program complements Biomeme’s expanding range of biosecurity testing solutions, including the identification of biowarfare agents, infectious diseases, industrial hygiene, and environmental health CONOPs.

The pandemic, along with the effects of war, has left Ukraine vulnerable to a greater risk of infectious diseases, making the implementation of an on-the-ground biosecurity program crucial. Concentric by Ginkgo, Ginkgo Bioworks’ biosecurity and public health unit, has partnered with the Ukraine Ministry of Health to design a practical solution for monitoring biological threats found in critical wastewater systems, including sewage systems and natural waterways.

For this pilot program, Biomeme’s real-time RT-PCR platform, known for its portability and sensitivity, has been chosen. The platform simplifies shipping logistics and allows for GPS-tagged data to be wirelessly synced to the Biomeme Cloud, enabling data analysis on the go. Biomeme’s system employs pre-aliquoted, pre-mixed, and shelf-stable consumables, making it an ideal solution for low-resource areas that require accessible and accurate testing options. The system is capable of detecting, differentiating, and quantifying up to 27 molecular targets, making it a good fit for syndromic PCR panels that can differentiate between multiple pathogens. Over the years, Biomeme and Ginkgo Bioworks have collaborated on several successful biosurveillance initiatives, and the use of Biomeme’s sample-to-answer system in this pilot program will make epidemiological surveillance and biological threat monitoring in complex settings and hard-to-reach environments easier.

Mike Smith, Senior Director, Commercial stated, “Our partnership with Concentric by Ginkgo continues to strengthen because of our alignment and focus on Biosecurity. We share in their belief that a “biosecurity in a box” model could be a way to manage biosecurity concerns in crisis zones, hard-to-reach environments, and low-resource areas.”

Biomeme’s product line is designed to address biosecurity limitations in public health infrastructure during moments of emergency, conflict, and disaster. The company’s technology has been optimized to provide practical, easy-to-use solutions for monitoring pathogens in wastewater systems, regardless of location.

For more information on this collaboration, please visit biomeme.com.

ABOUT BIOMEME

Biomeme revolutionized molecular detection in 2012 when it created the first smartphone add-on capable of performing real-time PCR. Since its inception, Biomeme has used advanced biology and chemistry, along with world-class hardware and software engineering, to create elegant solutions to complex problems. Headquartered in Philadelphia, USA, Biomeme offers a full suite of end-to-end mobile molecular solutions that perform to the gold standard used by the world’s most advanced central labs yet require no lab equipment or special experience to use. To find out more about Biomeme, visit biomeme.com or follow us on Twitter (@BiomemeInc) or LinkedIn.

ABOUT GINKGO BIOWORKS

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo’s biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as Twitter (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), or LinkedIn.

ABOUT THE PUBLIC HEALTH CENTER OF THE UKRAINE MINISTRY OF HEALTH

State Institution “Public Health Center of the Ministry of Health of Ukraine” (UPHC) is a healthcare institution responsible for maintaining and strengthening public health, social and hygienic monitoring of diseases, epidemiological surveillance and biological safety, group and population prevention of morbidity, epidemic control and strategic management in the field of public health. It was formed in pursuance of the order of the Cabinet of Ministers of Ukraine by Order of the Ministry of Health of Ukraine dated September 18, 2015 No. 604. The main task of the UPHC is activities in the field of public health. The UPHC performs treatment and prevention, scientific, practical, organizational and methodological functions in the field of healthcare in order to ensure the quality of treatment of patients with socially dangerous diseases, in particular HIV / AIDS, tuberculosis, drug addiction, viral hepatitis, etc., disease prevention in the context of development public health systems. UPHC participates in the formation of regulatory policy and interacts with other ministries, research institutions, international, public organizations working in the field of public health and combating socially dangerous diseases.

Share article on social media or email:



Global Registries Could Change the Lives of Hundreds of Millions of Rare Disease Patients Everywhere


News Image

While an astounding number of patients are available for clinical trials worldwide, U.S. sponsors of potential treatments often fail to meet their target patient enrollment as they are mostly focused on the U.S. and E.U. markets during the clinical development process.

Globally, between 263 and 446 million people are estimated to suffer from one of 11,000 named rare diseases — about half of those affected are children.(1) The term ‘rare disease’ refers to a chronic and severe disorder that affects fewer than 200,000 Americans, is poorly understood, and lacks effective treatment. Because the incidence of each disease is low within individual countries, data is extremely limited. In the U.K. and the U.S., a rare disease patient will see an average of seven physicians over the course of five to seven years before receiving a diagnosis.(2) A global rare disease patient registry is imperative to gather enough data to make an impact.(3) Dr. Harsha Rajasimha of the humanitarian non-profit IndoUSrare is forming international partnerships to develop global patient registries for each rare disease or a subset of similar rare diseases.

Dr. Rajasimha notes, “While an astounding number of patients are available for clinical trials worldwide, U.S. sponsors of potential treatments often fail to meet their target patient enrollment as they are mostly focused on the U.S. and E.U. markets during the clinical development process. This is a problem that a global patient registry could ameliorate. However, successfully creating such registries will require new strategies to motivate rare disease patients to participate.”

The problem is that most countries do not yet have patients’ health information in digital formats that are ready for consumption for the purposes of R&D. Patient registries are necessary prerequisites that are convenient and cost-effective tools for the R&D of orphan drugs.(4) They provide data on how a disease develops in different persons, the symptoms of the disease, and the effects of treatment.(5)

Dr. Rajasimha explains, “The creation & maintenance of global patient registries need to be led by qualified patient advocacy groups for rare diseases, and must overcome numerous challenges such as data protection regulations, language barriers, cultural barriers, and technical barriers. The National Institutes of Health and the FDA acknowledge that well-designed patient registries and natural history studies are critical for rare diseases as published scientific literature is limited. Patients are the scientists who have the experience living with these diseases, making them natural experts. Capturing these observations under the supervision of qualified clinical investigators can serve as a foundation for the success of future clinical trials, the evaluation of treatments, and understanding the heterogeneity in disease progression from patient to patient.”

Another challenge is the lack of a comprehensive natural history of rare diseases, which is vital to planning and guiding a study.(5) Without it, researchers and practitioners must start from scratch each time. The U.S. National Organization for Rare Disorders (NORD) advocates for registry data, stating it unites the patient and research community, helps develop treatments, and improves the quality of care.(7)

When well-documented patients from such patient registries and industry partners are ready to pursue a promising candidate orphan drug or gene therapy, much hope rests on clinical trials, the process by which regulators evaluate therapies for safety and efficacy. A stumbling block in executing clinical trials for orphan therapies is applying the same expectations from the conventional trial designs applied for common indications such as the use of placebos. Individuals with rare diseases, who have struggled for years with hard-to-diagnose and chronic symptoms, are reasonably unwilling to risk being part of a placebo group when what they desperately need is treatment. Instead, an open-label or crossover study can benefit both researchers and patients.

In an open-label study, participants know what treatment they are receiving. Sometimes a conventional double-blind clinical trial using a placebo control group can be followed by a long-term open-label study.(6) In this way, even those patients who initially receive the placebo can receive the investigational medicine.

In a crossover study, all participants receive the same two (or more) treatments. Groups are divided randomly and receive the available treatments in different sequences with a break in between. These clinical trial formats offer hope to individuals with rare diseases, increasing the number willing to participate. With such low incidences of these rare conditions, every patient is valuable.

Not all patients with rare diseases are willing to come in regularly over extended periods for observation. NORD advocates making it as easy as possible for patients so research can progress. They propose combining studies with clinical visits, synchronizing patient forms, and getting data through telehealth visits as often as possible.(7) Patient-friendly strategies and technology are essential to gathering enough information to further the research and treatment of rare diseases. In particular, decentralized trial designs and digital remote monitoring devices encourage maximum participation.

IndoUSrare currently provides free patient concierge services for rare disease patients globally on their technology platform. The IndoUSrare Corporate Alliance is committed to leveraging shared resources and developing long-term collaborations across borders for the cost-effective advancement of R&D for rare diseases. Dr. Rajasimha insists, “We cannot develop effective treatments for rare diseases without true international collaborations. The Rare Diseases communities and the Orphan Drugs Industry have been conducting research and development in small, biased populations located in the U.S. and E.U. IndoUSrare’s mission is to create bridges between geographic silos, people, cultures, and medical science to find breakthrough therapies and cures for rare diseases.” The organization invites all stakeholders of rare diseases to join their Indo-US RARE Summit on October 29-30, 2023, at the George Mason University Campus in Arlington, VA.

About IndoUSrare

IndoUSrare is a humanitarian non-profit 501(c)(3) tax-exempt public charity organization based in the U.S. Founder and Chairman Dr. Harsha Rajasimha, who lost a child to a rare disease in 2012, has been a rare disease advocate for more than 10 years. To address the unmet needs of diverse patients with rare diseases globally, the leadership team comprised of experienced professionals from research, advocacy, regulatory, and drug development seeks to build cross-border collaborations connecting stakeholders of rare diseases in low- and middle-income regions such as India, with their counterparts and clinical researchers in the U.S. to improve the diversity of clinical trial participants, accelerate research and development, and improve equitable access to life-saving therapies to diverse populations of rare disease patients. Visit https://indousrare.org.

References: 

1. Millán, José M.; García-García, Gema. “Genetic Testing for Rare Diseases.” April 12, 2022, Diagnostics (Basel), ncbi.nlm.nih.gov/pmc/articles/PMC9028486/.

2. Ornskov, Flemming. “350 million people suffer from rare diseases. Here’s how tech can help.” Jan 19, 2018, World Economic Forum, weforum.org/agenda/2018/01/350-million-people-suffer-from-rare-diseases-heres-how-tech-can-help/.

3. Agency for Healthcare Research and Quality. “Registries for Evaluating Patient Outcomes: A User’s Guide: 4th Edition.” Sep 21, 2020, Effective Health Care Program, effectivehealthcare.ahrq.gov/products/registries-guide-4th-edition/users-guide.

4. Gliklich RE; Dreyer NA; Leavy MB. “Registries for Evaluating Patient Outcomes: A User’s Guide [Internet]. 3rd edition.” April 2014, Agency for Healthcare Research and Quality (US), ncbi.nlm.nih.gov/books/NBK208643/.

5. Bollerman, Cody J. “Common Problems in Clinical Trials for Rare Diseases.” May 11, 2020, Clinical Researcher, acrpnet.org/2020/05/11/common-problems-in-clinical-trials-for-rare-diseases/

6. Concert Pharmaceuticals Inc. “Understanding Clinical Trial Terminology: What Is An Open Label Clinical Trial?.” June 24th, 2019, concertpharma.com/understanding-clinical-trial-terminology-what-is-an-open-label-clinical-trial/.

7. Vita Staff. “Explainer: What Are Natural History Studies?.” March 18, 2021, CSL Behring, cslbehring.com/vita/2021/what-are-natural-history-studies

Faruk Bhagani Joins Element Blue’s Healthcare Technology Practice


Faruk’s depth of experience will greatly contribute to the continued growth of our intelligent automation practice. – Steven Gerhardt, CEO

Element Blue, a Houston-based healthcare technology consultancy and certified custom solution provider, announced that Faruk Bhagani has joined the firm as senior vice president, sales.

“We are pleased to welcome Faruk to Element Blue,” said Steven Gerhardt, Managing Partner & CEO. “His industry knowledge and experience in leading high-performing sales teams will benefit our clients and is integral to the continued growth of our intelligent automation healthcare practice.”

“I have observed and been impressed by Element Blue’s success for many years,” said Bhagani. “I look forward to contributing to its vision for the future as the healthcare sector further embraces innovative technology solutions.”

Bhagani brings more than two decades of international entrepreneurial and high-tech sales leadership and a history of generating 8-figure sales revenues to the role at Element Blue. Most recently at Salesforce, he supported enterprise professional services firms in leveraging the Salesforce portfolio to transform client digital journeys.

Active in his community both professionally and personally, Bhagani is a founding member of OPEN SoCal, a global non-profit that promotes entrepreneurial and professional development for the South Asian diaspora across professional industries. In addition, he works with Houston-area non-profits to extend and further their causes by serving as master of ceremony and host for their fundraising and community development events.

Bhagani received his master’s degree in financial strategy from Oxford University and his undergraduate degree from the University of Houston.

About Element Blue

Element Blue (http://www.elementblue.com) enables healthcare systems to transform the patient experience and reduce costs through increased personalization and intelligent automation. The practice’s Blueprint Services Framework impacts patient access, referrals, digital marketing and the revenue cycle at the most critical stages of the customer journey, resulting in a seamless encounter across the system.

By empowering patients and employees to actively manage their unique healthcare experiences, Element Blue increases the satisfaction of every health system consumer: customers, patients and members.

Houston-based, Element Blue has offices in Dubai, Hyderabad, Nairobi, Lima, Buenos Aires, and San Jose. For more information, please go to ElementBlue.com.

Share article on social media or email:

The National Infertility Association to Observe National Infertility Awareness Week®


Let’s use National Infertility Awareness Week to raise our voices, talk about the issues too many of us face, and ensure we continue supporting those most in need.

RESOLVE: The National Infertility Association will recognize National Infertility Awareness Week®, April 23 through April 29, 2023. The movement brings together millions of Americans who want to remove the stigmas and barriers that stand in the way of building families. RESOLVE will rally the infertility community to raise awareness about the significant lack of access to family building options and emotional support for millions of women and men struggling to build a family. #FindYourVoice will be a message found on the official NIAW website and throughout RESOLVE’s social media campaigns.

“Millions of people face barriers to building a family whether they are facing infertility, having trouble sustaining a pregnancy, or people in the LGBTQ+ community. The barriers include access to care, financial limitations, and even proposed legislation and policies which could make it impossible to access family building options like IVF. We encourage those who struggle to build a family to use our resources and find their voice,” said Barbara Collura, RESOLVE’s President/CEO. “Let’s use NIAW to raise our voices, talk about the issues too many of us face, and ensure we continue supporting those most in need.”

Throughout NIAW, the infertility and family building community will take to social media and share their stories in different ways through RESOLVE’s 5-Day Challenge and lead the conversation about challenges to family building and methods of resolution. Through national media, social media, and fundraising, the infertility community will take action to increase awareness of infertility to remove stigmas and improve access to family building options.

On Tuesday, April 25, in partnership with the American Society for Reproductive Medicine, RESOLVE will bring more than 400 advocates to virtual meetings with hundreds of Members of Congress. The annual Advocacy Day will focus on access to care issues like insurance coverage for IVF for federal employees, protecting access to IVF, the adoption tax credit, and removing barriers to medical treatment for our Veterans and servicemembers.

RESOLVE’s National Infertility Awareness Week 2023 is supported by the following partners: Church & Dwight Co., Inc. makers of First Response™; CooperSurgical; EMD Serono; Encompass Fertility by CVS; Ferring Pharmaceuticals; Organon; Progyny; TMRW; and US Fertility.

NIAW became a federally recognized health observance by the Department of Health and Human Services in 2010. RESOLVE can provide experts for interviews on all aspects of infertility, and personal patient stories from women and men struggling to build their families. Find out more about NIAW at infertilityawareness.org.

# # #

About RESOLVE: The National Infertility Association: Established in 1974, RESOLVE: The National Infertility Association is a non-profit organization with the only established, nationwide network mandated to promote reproductive health and to ensure equal access to all family building options for men and women experiencing infertility or other reproductive disorders. One in eight U.S. couples of childbearing age has trouble conceiving or carrying a pregnancy to term. RESOLVE addresses this public health issue by providing community to these women and men, connecting them with others who can help, empowering them to find resolution and giving voice to their demands for access to all family building options. For more information, visit http://www.RESOLVE.org.

Share article on social media or email:

Senior Care Franchise Right at Home Targets Expansion in Daytona Beach; Looking to Meet Qualified Prospective Franchisees Wanting to Make a Difference in Their Community


Right at Home, the 650-plus location in-home health care concept helping seniors and adults with disabilities live comfortably at home, is looking to expand in Daytona Beach, Florida. The opportunity gives local entrepreneurs a chance to make a difference in their communities and provide peace of mind to families needing care.

Right at Home employs professionally-trained caregivers to provide care and assistance to seniors and adults with disabilities who wish to remain in the comfort and safety of their own home or current living arrangement. With over 26 years of experience providing essential care in more than 650 locations across eight countries, Right at Home has become one of the world’s largest in-home health care franchises.

With persons aged 65 and over making up 20% of its population, Daytona Beach is primed for Right at Home’s services. In general, Florida has the second-highest population of seniors out of all 50 states. And as thousands of Americans are crossing the 65-year-old threshold every day, a phenomenon coined the “silver tsunami,” there will be continued demand for the franchise’s services in the state. In fact, there are already 57 Right at Home territories sold in Florida.

“Right at Home starts with our passionate franchise owners, and we’re excited to partner with the people of Daytona Beach,” said Jennifer Chaney, Vice President of Franchise Development. “We are seeking passionate individuals who aren’t just looking for a business to make a living. Entrepreneurs should choose Right at Home to make a positive impact on their communities and the people for whom they provide care. Our mission is to improve the quality of life for those we serve.”

With its eyes on Daytona Beach, the industry-leading in-home health care concept is seeking qualified franchise partners to provide its much-needed services within three territories in the market.

Right at Home is seeing an increased demand for quality in-home care services across the country as the baby boomer generation reaches its senior years. During 2020 and 2021, the franchise not only survived the height of the pandemic but came out of it stronger than ever– exceeding growth goals by 40%. And in 2022, Right at Home picked up even more momentum as it continued to bring its best-in-class in-home health care services to families in new markets across the country. This year, Right at Home is looking forward to building on that growth, including in Daytona Beach.

ABOUT RIGHT AT HOME:

Founded in 1995, Right at Home offers in-home care to seniors and adults with disabilities who want to live independently. Most Right at Home offices are independently owned and operated and directly employ and supervise all caregiving staff. Each caregiver is thoroughly screened, trained, and bonded/insured before entering a client’s home. Right at Home’s global office is based in Omaha, Nebraska, with more than 650 franchise locations in the U.S. and eight other countries. For more information on Right at Home, visit http://www.rightathome.net or read the Right at Home blog at http://www.rightathome.net/blog. If you are interested in learning more or in owning a Right at Home franchise, please visit us at: https://rightathomefranchise.com/ or to read more about franchise ownership, visit our blog at: https://rightathomefranchise.com/forc/.

Share article on social media or email:

Next-Generation Complement Therapeutics — Exploring Challenges and Solutions from Bench to Bedside, Upcoming Webinar Hosted by Xtalks


The rise in the number of conditions linked to dysregulation of the complement system clearly underscores the potential of complement-modulating therapeutics.

Complement is an important and integral part of the immune system known to interact with a wide range of tissues and cells across the body. However, only recently has it become an attractive therapeutic target. In this panel discussion, attendees will gain knowledge on the challenges and potentials of complement therapeutics from drug discovery all the way through to clinical testing.

The introduction of Eculizumab, the pioneering complement modulator, demonstrated that targeting the complement system is well-tolerated, provides beneficial treatment and can change, and potentially save, lives. The rise in the number of conditions linked to dysregulation of the complement system clearly underscores the potential of complement-modulating therapeutics.

However, many attempts to make new drugs have failed. This has served as a valuable lesson to scientists and researchers, highlighting the importance of understanding the complexities of the complement system and the need for specialized tools to successfully develop effective drugs.

Over the last few decades, multiple initiatives have been launched — because of both the success with Eculizumab and a better understanding of the complement system — ranging from academic laboratories to large pharmaceutical companies exploring further the potential of regulating the complement system. A considerable number of these complement therapeutics have entered clinical development, and several are even in advanced late trial stages.

Equipped with these insights and the technical advancements in biological drug design, novel complement modulating drugs are emerging to avoid previous pitfalls and thus increase the chances of clinical success. This creates a promising outlook for those aiming to leverage the potential therapeutic applications of modulating the complement system and bringing it to the clinic to improve the health of patients.

Register for this webinar to hear from experts on next-generation complement therapeutics as they provide perspectives and insights from each stage of the drug development process.

Join Dr. Michael Schwenkert, Chief Technology Officer, Svar Life Science; Dr. Christoph Schmidt, Professor of Biochemical Pharmacy, Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg; Dr. Előd Körtvély, Principal Scientist, Pharma Research and Early Development (pRED), Roche Innovation Center; Dr. Sandra Wymann, Senior Manager, Translational Research, CSL Behring AG, for the live webinar on Tuesday, April 11, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Next-Generation Complement Therapeutics — Exploring Challenges and Solutions from Bench to Bedside.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Belt Technologies, Inc., introduces TruPulley line of products


This line of pulleys is a testament to our commitment to engineering excellence and innovation within the conveying system market. We know this new line will exceed customer expectations and are excited to see all the applications it will benefit.

Belt Technologies, Inc., a manufacturer of custom metal belt conveyor solutions for more than 50 years, is introducing the new TruPulleyTM line of products, which all work to monitor or regulate the tension, pace or tracking of a metal belt. The patent-pending TruTensionTM, TruPaceTM and TruTrackTM pulleys are available as standalone products or as part of a conveyor system designed by Belt Technologies engineers and manufactured in the United States.

“After years of dedication to creating these superior products, we are excited to finally release them to the world,” said Belt Technologies CEO Denis Gagnon. “This line of pulleys is a testament to our commitment to engineering excellence and innovation within the conveying system market. We know this new line will exceed customer expectations and are excited to see all the applications it will benefit.”

The TruTensionTM Pulley incorporates sensors to measure the tension of a steel belt, allowing users to optimize the belt’s performance and maximize its lifespan. The TruTensionTM pulley leverages a small, enclosed controller (separate from the pulley) that senses the bearing load in the pulley. Through a calibration process, the pulley measures the belt tension and displays it digitally on the controller display—making TruTensionTM a first of its kind in the marketplace.

The TruPaceTM Pulley consists of a thin-walled tube with end caps that add rigidity and allow for multiple mounting options for the end user. These pulleys can be accelerated very quickly with low power output and can be customized to meet customer specifications. Compared to standard pulley designs of similar diameter and width, the TruPaceTM Pulley offers a significant decrease in inertia to allow designers to specify smaller motors and gearboxes for their equipment.

The TruTrackTM Pulley precisely automates belt tracking by using a segmented roller design that moves with virtually no friction along the shaft between two edge guides, improving the lifespan of the belt. The segmented design of the TruTrackTM Pulley substantially reduces side loads on the belt, preventing damage to its edge and improving belt life in ways standard edge guides or flanges can’t.

“We are very proud of these products and the work that went into their development,” said Belt Technologies President Alan Wosky. “There are countless applications for these pulleys, and with our customization capabilities, the possibilities are endless.”

Belt’s PureSteel® products drive productivity with custom automation solutions complete with engineering support from concept to completion. Through sophisticated engineering, advanced manufacturing processes and unlimited custom designs, their products can suit any application.

About Belt Technologies

Belt Technologies, Inc., has been producing custom metal belt conveyor solutions for new and existing conveyor systems for more than five decades. Sophisticated engineering, advanced manufacturing processes, and an unlimited variety of configurations and coatings are available to custom-design belts to suit any application. Metal belts, timing belts, and metal drive tapes are superior, high-quality options for automated production and robotic facilities. A subsidiary, Belt Technologies Europe (BTE), located in Tyne and Wear in the U.K., serves as the sales office for Europe and Asia. To learn more about Belt Technologies and metal conveyor belts, visit belttechnologies.com.

Share article on social media or email: